Moreover, pharmacologic strategies such as metformin or GLP-1 receptor agonists are gaining interest not only for their metabolic benefits but also for their potential to improve mood and cognitive outcomes in patients with insulin resistance and treatment-resistant depression [62,69]. The gene discussed is GLP1R; the disease is depressive disorder.